PL4452267T3 - Pochodne 4-fenylo-tetrahydropirydyny do leczenia chorób słuchu - Google Patents

Pochodne 4-fenylo-tetrahydropirydyny do leczenia chorób słuchu

Info

Publication number
PL4452267T3
PL4452267T3 PL22844112.7T PL22844112T PL4452267T3 PL 4452267 T3 PL4452267 T3 PL 4452267T3 PL 22844112 T PL22844112 T PL 22844112T PL 4452267 T3 PL4452267 T3 PL 4452267T3
Authority
PL
Poland
Prior art keywords
phenyl
treating hearing
tetrahydropyridine derivatives
hearing diseases
diseases
Prior art date
Application number
PL22844112.7T
Other languages
English (en)
Inventor
Célia BELLINE
Marie-Pierre PASDELOU
Sylvie PUCHEU
Gaëlle NAERT
Cyrille SAGE
Mathieu SCHUE
Original Assignee
Cilcare Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cilcare Dev filed Critical Cilcare Dev
Publication of PL4452267T3 publication Critical patent/PL4452267T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL22844112.7T 2021-12-23 2022-12-23 Pochodne 4-fenylo-tetrahydropirydyny do leczenia chorób słuchu PL4452267T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21306931 2021-12-23
PCT/EP2022/087667 WO2023118544A1 (en) 2021-12-23 2022-12-23 4-phenyl-tetrahydropyridine derivatives for treating hearing diseases

Publications (1)

Publication Number Publication Date
PL4452267T3 true PL4452267T3 (pl) 2025-06-23

Family

ID=79831487

Family Applications (1)

Application Number Title Priority Date Filing Date
PL22844112.7T PL4452267T3 (pl) 2021-12-23 2022-12-23 Pochodne 4-fenylo-tetrahydropirydyny do leczenia chorób słuchu

Country Status (19)

Country Link
US (1) US20230390273A1 (pl)
EP (2) EP4452267B1 (pl)
JP (1) JP2024546180A (pl)
KR (1) KR20240125025A (pl)
CN (1) CN118715014A (pl)
AU (1) AU2022419307A1 (pl)
CA (1) CA3241657A1 (pl)
DK (1) DK4452267T3 (pl)
ES (1) ES3030316T3 (pl)
FI (1) FI4452267T3 (pl)
HR (1) HRP20250600T1 (pl)
HU (1) HUE071387T2 (pl)
IL (1) IL313499A (pl)
LT (1) LT4452267T (pl)
MX (1) MX2024007944A (pl)
PL (1) PL4452267T3 (pl)
PT (1) PT4452267T (pl)
SI (1) SI4452267T1 (pl)
WO (1) WO2023118544A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL4452267T3 (pl) * 2021-12-23 2025-06-23 Cilcare Dev Pochodne 4-fenylo-tetrahydropirydyny do leczenia chorób słuchu

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2762514B1 (fr) 1997-04-29 1999-10-22 Sanofi Sa Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments pour le traitement des maladies entrainant une demyelinisation
MXPA02009071A (es) * 2000-03-17 2003-05-23 Alcon Inc Compuestos con actividad agonista de 5-ht 1a para tratar glaucoma..
US20100130537A1 (en) * 2007-04-26 2010-05-27 Eisai R&D Management Co., Ltd Cinnamide compounds for dementia
BRPI0910850B1 (pt) * 2008-04-21 2022-06-14 Otonomy, Inc. Composição intratimpânica compreendendo fator neurotrófico de crescimento derivado do cérebro (bdnf) para o tratamento ou prevenção da perda auditiva
EP3406259A1 (en) * 2017-05-24 2018-11-28 Dompé farmaceutici S.p.A. Neurotrophins for use in the treatment of hearing loss
PL4452267T3 (pl) * 2021-12-23 2025-06-23 Cilcare Dev Pochodne 4-fenylo-tetrahydropirydyny do leczenia chorób słuchu

Also Published As

Publication number Publication date
ES3030316T3 (en) 2025-06-27
CN118715014A (zh) 2024-09-27
EP4545066A3 (en) 2025-06-25
MX2024007944A (es) 2024-09-10
DK4452267T3 (da) 2025-05-26
PT4452267T (pt) 2025-05-16
KR20240125025A (ko) 2024-08-19
HRP20250600T1 (hr) 2025-07-18
FI4452267T3 (fi) 2025-06-03
IL313499A (en) 2024-08-01
EP4545066A2 (en) 2025-04-30
SI4452267T1 (sl) 2025-07-31
LT4452267T (lt) 2025-06-10
AU2022419307A1 (en) 2024-06-27
CA3241657A1 (en) 2023-06-29
JP2024546180A (ja) 2024-12-17
EP4452267A1 (en) 2024-10-30
WO2023118544A1 (en) 2023-06-29
EP4452267B1 (en) 2025-04-23
US20230390273A1 (en) 2023-12-07
HUE071387T2 (hu) 2025-08-28

Similar Documents

Publication Publication Date Title
IL277333A (en) Methods for treating eye diseases
IL287168A (en) Kit of pyrrolotriazine derivatives for the treatment of diseases mediated by pdgfra
EP3759088B8 (en) Triazine derivatives for treating diseases relating to neurotrophins
HUE070387T2 (hu) Indazolil-izoxazol származékok betegségek, mint például rák kezelésére
IL313499A (en) Derivatives of 4-phenyl-tetrahydropyridine for the treatment of hearing diseases
IL290770A (en) Compounds and methods for treating oxalate-related diseases
GB202003722D0 (en) Treatment
HK40112028A (en) 4-phenyl-tetrahydropyridine derivatives for treating hearing diseases
GB202006236D0 (en) New treatment
GB202002711D0 (en) Treatment
HK40081973A (en) Combination treatment for fumarate-related diseases
HK40110531A (en) Methods for treating respiratory diseases
AU2021903441A0 (en) Methods for treating respiratory diseases
HK40086640A (en) Method for the treatment nlrp3-associated diseases
AU2021901393A0 (en) Treatment for alopecia
HK40067840A (en) Methods for treating ocular diseases
HK40076432A (en) Compounds and methods for treating oxalate-related diseases
HK40095640A (en) Treatment for schizophrenia
AU2021901964A0 (en) New treatment for neurodegenerative diseases
GB202300613D0 (en) Tobacco treatment
GB202300605D0 (en) Tobacco treatment
PL4366727T3 (pl) Nowe koncepcje terapeutyczne w leczeniu zapalenia ucha
HK40100272A (en) Methods for treating inflammatory skin conditions
HK40112478A (en) Treatment for inflammatory disease
AU2023902197A0 (en) Treatment for tinnitus